A detailed history of Parallel Advisors, LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 4 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4
Previous 4 -0.0%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$20.27 - $42.44 $81 - $169
4 New
4 $0
Q4 2022

Feb 03, 2023

BUY
$25.35 - $31.96 $76 - $95
3 New
3 $0
Q1 2022

Apr 28, 2022

SELL
$23.5 - $35.38 $211 - $318
-9 Closed
0 $0
Q4 2021

Jan 20, 2022

BUY
$29.21 - $44.64 $262 - $401
9 New
9 $0

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.